Accelerated bacterial identification with MALDI-TOF MS leads to fewer diagnostic tests and cost savings
Introduction: Rapid microbiology reporting can enhance both clinical and economic outcomes. Material and Methods: This three-year, quasi-experimental study, single-group pretest¿posttest study, conducted at a university medical center, aimed to evaluate the clinical and economic impact of rapid micr...
| Autores: | , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2024 |
| País: | España |
| Institución: | Universidad Pública de Navarra |
| Repositorio: | Academica-e. Repositorio Institucional de la Universidad Pública de Navarra |
| OAI Identifier: | oai:academica-e.unavarra.es:2454/53621 |
| Acceso en línea: | https://hdl.handle.net/2454/53621 |
| Access Level: | acceso abierto |
| Palabra clave: | Clinical impact Economic impact Fast information Diagnostics MALDI-TOF MS Costs |
| Sumario: | Introduction: Rapid microbiology reporting can enhance both clinical and economic outcomes. Material and Methods: This three-year, quasi-experimental study, single-group pretest¿posttest study, conducted at a university medical center, aimed to evaluate the clinical and economic impact of rapid microbiological identification reporting using MALDI-TOF MS. A total of 363 consecutive hospitalized patients with bacterial infections were evaluated, comparing a historical control group (CG, n = 183) with an intervention group (IG, n = 180). In the CG, microbiological information (bacterial identification and antibiotic susceptibility) was provided between 18:00 and 22:00 h, while in the IG, bacterial identification was reported between 12:00 and 14:00 h, and antibiotic susceptibility was reported between 18:00 and 22:00 h. Results: The IG demonstrated a significant reduction in the number of patients undergoing Microbiology (p = 0.01), Biochemistry (p = 0.05), C-Reactive Protein (p = 0.02), Radiological Tests (p = 0.05), Computed Tomography Tests (p = 0.04), and Pathology (p = 0.01). However, no statistically significant reduction was observed in economic costs related to microbiological testing (p = 0.76) or antibiotic consumption (p = 0.59). The timely reporting of microbiological identification to clinicians resulted in fewer patients undergoing additional diagnostic tests, ultimately contributing to reduced healthcare resource utilization without adversely affecting clinical outcomes. |
|---|